Idera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oncology and rare diseases. The Company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: (1) Toll-like receptor, or TLR, targeting technology and (2) our third-generation antisense, or 3GA, technology. They developed these platforms based on scientific expertise and pioneering work with synthetic oligonucleotides.
Using TLR targeting technology the Company designs synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. Using their 3GA technology they are developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera believes that 3GA technology may potentially reduce the immunotoxicity and increase the potency of earlier generation antisense and RNA interference, or RNAi, technologies.
The Company's business strategy is focused on the clinical development of drug candidates for oncology and rare diseases characterized by small, well-defined patient populations with serious unmet medical needs. Idera believes they can develop and commercialize these targeted therapies on their own. To the extent they seek to develop drug candidates for broader disease indications, they explore potential collaborative alliances.
I'm extremely attracted to this company's revenue growth and its liability coverage, but little else is available for determining this company's potential going forward. So with so little to go on fundamentally, I rely heavily on the price chart. On the chart it can easily be seen that there's a little resistance at four, five and six dollars per share but after that there's pretty much clear skies.
So with individual shares being this inexpensive, I'll pick up a couple hundred shares and see what happens. This stock could easily double or triple over the next year. Or it could be just another mistake and learning experience.
Using TLR targeting technology the Company designs synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. Using their 3GA technology they are developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera believes that 3GA technology may potentially reduce the immunotoxicity and increase the potency of earlier generation antisense and RNA interference, or RNAi, technologies.
The Company's business strategy is focused on the clinical development of drug candidates for oncology and rare diseases characterized by small, well-defined patient populations with serious unmet medical needs. Idera believes they can develop and commercialize these targeted therapies on their own. To the extent they seek to develop drug candidates for broader disease indications, they explore potential collaborative alliances.
I'm extremely attracted to this company's revenue growth and its liability coverage, but little else is available for determining this company's potential going forward. So with so little to go on fundamentally, I rely heavily on the price chart. On the chart it can easily be seen that there's a little resistance at four, five and six dollars per share but after that there's pretty much clear skies.
So with individual shares being this inexpensive, I'll pick up a couple hundred shares and see what happens. This stock could easily double or triple over the next year. Or it could be just another mistake and learning experience.
Idera Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.
(Summary) (Company) (Chart)
| 11 October 2017 Price $2.77 1yr Target $5.75 Analysts 4 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 107.58% Yield 0.00% 1yr Tot Return 107.58% P/E --- PEG --- Beta 2.14 | EPS (ttm) $-0.35 EPS next yr $-0.50 Forward P/E --- EPS next 5yr --- 1yr Price Support --- Market Cap $376.08 Mil Revenues $16.20 Mil Earnings $-48.60 Mil Profit Margin --- Quick Ratio 11.10 Current Ratio 11.10 Debt/Equity 0.01 | 1yr RevGR 6405.62% 3yr RevGR 587.60% 5yr RevGR 214.08% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -55.10% ROE -61.10% |
| |
Print 
PDF
RSS Feed
